AMAN U BUZDAR

TitleProfessor
InstitutionMD Anderson
DepartmentBreast Medical Oncology
Address7007 Bertner Avenue
Houston TX 77054-3403
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Ingle JN, Kalari KR, Barman P, Shepherd LE, Ellis MJ, Goss PE, Buzdar AU, Robson ME, Cairns J, Carlson EE, Eyman Casey A, Hoskin TL, Goodnature BA, Haddad TC, Goetz MP, Weinshilboum RM, Wang L. Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. Pharmacogenet Genomics. 2021 01; 31(1):1-9. PMID: 32649577.
      Citations:    Fields:    Translation:Humans
    2. Cairns J, Ingle JN, Dudenkov TM, Kalari KR, Carlson EE, Na J, Buzdar AU, Robson ME, Ellis MJ, Goss PE, Shepherd LE, Goodnature B, Goetz MP, Weinshilboum RM, Li H, Bari MG, Wang L. Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. JCI Insight. 2020 08 20; 5(16). PMID: 32701512.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    3. Dudenkov TM, Liu D, Cairns J, Devarajan S, Zhuang Y, Ingle JN, Buzdar AU, Robson ME, Kubo M, Batzler A, Barman P, Jenkins GD, Carlson EE, Goetz MP, Northfelt DW, Moreno-Aspitia A, Desta Z, Reid JM, Kalari KR, Wang L, Weinshilboum RM. Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2. Clin Pharmacol Ther. 2019 07; 106(1):219-227. PMID: 30648747.
      Citations: 2     Fields:    Translation:HumansCells
    4. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig GW, Royce ME, Hunt KK. Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):45-50. PMID: 30193295.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    5. Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs. 2018 04; 36(2):299-306. PMID: 29374384.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    6. Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER. Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial. Ann Oncol. 2017 05 01; 28(5):1070-1077. PMID: 28453704.
      Citations: 22     Fields:    Translation:Humans
    7. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21553292.
      Citations: 5     Fields:    Translation:Humans
    8. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16870082.
      Citations: 6     Fields:    Translation:Humans
    9. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18581139.
      Citations: 3     Fields:    Translation:Humans
    10. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 3407623.
      Citations:    Fields:    Translation:Humans
    11. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8197782.
      Citations: 3     Fields:    Translation:Humans
    12. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8490917.
      Citations: 5     Fields:    Translation:Humans
    13. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18083636.
      Citations: 299     Fields:    Translation:Humans
    14. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 24562447.
      Citations: 44     Fields:    Translation:Humans
    15. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 25888246.
      Citations: 11     Fields:    Translation:Humans
    16. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 26078431.
      Citations: 15     Fields:    Translation:Humans
    17. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 2358837.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    18. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15639680.
      Citations: 512     Fields:    Translation:Humans
    19. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 28135148.
      Citations: 119     Fields:    Translation:Humans
    20. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 27866278.
      Citations: 2     Fields:    Translation:Humans
    21. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 28275168.
      Citations: 10     Fields:    Translation:Humans
    22. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 28429243.
      Citations: 10     Fields:    Translation:Humans
    23. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 2569033.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    24. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8460868.
      Citations:    Fields:    Translation:Humans
    25. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8708708.
      Citations: 133     Fields:    Translation:Humans
    26. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15701878.
      Citations:    Fields:    Translation:Humans
    27. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15701885.
      Citations: 7     Fields:    Translation:Humans
    28. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12756078.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    29. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16467115.
      Citations: 2     Fields:    Translation:Humans
    30. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17200359.
      Citations: 139     Fields:    Translation:HumansCTClinical Trials
    31. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16467123.
      Citations: 2     Fields:    Translation:Humans
    32. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 2914290.
      Citations: 3     Fields:    Translation:Humans
    33. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 3819804.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    34. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 6824391.
      Citations: 11     Fields:    Translation:Humans
    35. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8092114.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    36. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9850015.
      Citations: 31     Fields:    Translation:Humans
    37. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11306725.
      Citations: 28     Fields:    Translation:Humans
    38. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9365184.
      Citations: 3     Fields:    Translation:Humans
    39. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11283133.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    40. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12088118.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    41. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15023242.
      Citations: 13     Fields:    Translation:Humans
    42. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12897330.
      Citations: 13     Fields:    Translation:Humans
    43. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15369444.
      Citations: 16     Fields:    Translation:Humans
    44. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15221988.
      Citations: 191     Fields:    Translation:Humans
    45. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16505422.
      Citations: 173     Fields:    Translation:Humans
    46. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15042669.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    47. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17293601.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    48. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16896004.
      Citations: 256     Fields:    Translation:Humans
    49. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16926572.
      Citations: 33     Fields:    Translation:Humans
    50. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17647266.
      Citations: 12     Fields:    Translation:Humans
    51. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 20133263.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    52. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22084362.
      Citations: 27     Fields:    Translation:Humans
    53. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 1683908.
      Citations: 124     Fields:    Translation:HumansCTClinical Trials
    54. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 1804815.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    55. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 470088.
      Citations: 11     Fields:    Translation:Humans
    56. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 480951.
      Citations: 3     Fields:    Translation:Humans
    57. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 445325.
      Citations: 7     Fields:    Translation:Humans
    58. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 369682.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    59. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 387212.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    60. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 6180820.
      Citations: 3     Fields:    Translation:Humans
    61. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 3768878.
      Citations: 2     Fields:    Translation:Humans
    62. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 3755282.
      Citations: 6     Fields:    Translation:Humans
    63. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 3755648.
      Citations: 7     Fields:    Translation:Humans
    64. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 3880657.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    65. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 3179923.
      Citations:    Fields:    Translation:Humans
    66. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 7260870.
      Citations: 11     Fields:    Translation:Humans
    67. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 7300363.
      Citations: 1     Fields:    Translation:Humans
    68. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 1403033.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    69. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 6364779.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    70. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 6396767.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    71. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 6547638.
      Citations: 2     Fields:    Translation:Humans
    72. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8646517.
      Citations: 3     Fields:    Translation:Humans
    73. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 7606728.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    74. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 6883292.
      Citations: 1     Fields:    Translation:Humans
    75. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 6896794.
      Citations:    Fields:    Translation:Humans
    76. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 6668494.
      Citations: 24     Fields:    Translation:Humans
    77. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 7896543.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    78. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9314293.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    79. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9537204.
      Citations: 1     Fields:    Translation:Humans
    80. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 10321507.
      Citations: 7     Fields:    Translation:Humans
    81. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 10619453.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    82. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9689981.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    83. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9374089.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    84. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 10765118.
      Citations: 13     Fields:    Translation:Humans
    85. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 10874521.
      Citations: 1     Fields:    Translation:Humans
    86. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9316752.
      Citations: 2     Fields:    Translation:Humans
    87. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 10682660.
      Citations: 8     Fields:    Translation:Humans
    88. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11850214.
      Citations: 3     Fields:    Translation:Humans
    89. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11916228.
      Citations: 14     Fields:    Translation:Humans
    90. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11916231.
      Citations: 2     Fields:    Translation:Humans
    91. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12436453.
      Citations: 1     Fields:    Translation:Humans
    92. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12379069.
      Citations: 88     Fields:    Translation:Humans
    93. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11004328.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    94. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12888362.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    95. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12766883.
      Citations: 2     Fields:    Translation:Humans
    96. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 14667279.
      Citations: 3     Fields:    Translation:Humans
    97. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12752630.
      Citations:    Fields:    Translation:Humans
    98. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15625359.
      Citations: 77     Fields:    Translation:HumansCTClinical Trials
    99. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 14745865.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    100. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15241821.
      Citations: 10     Fields:    Translation:Humans
    101. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15448010.
      Citations: 10     Fields:    Translation:HumansCells
    102. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16912252.
      Citations: 11     Fields:    Translation:Humans
    103. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16467120.
      Citations: 37     Fields:    Translation:Humans
    104. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15852360.
      Citations: 25     Fields:    Translation:Humans
    105. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16761927.
      Citations:    Fields:    Translation:Humans
    106. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16444747.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    107. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17694554.
      Citations: 64     Fields:    Translation:Humans
    108. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17149760.
      Citations: 15     Fields:    Translation:Humans
    109. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18560403.
      Citations: 10     Fields:    Translation:Humans
    110. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18667396.
      Citations: 13     Fields:    Translation:Humans
    111. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18703382.
      Citations: 61     Fields:    Translation:Humans
    112. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 19959074.
      Citations: 36     Fields:    Translation:HumansAnimals
    113. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21209588.
      Citations: 14     Fields:    Translation:Humans
    114. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21221190.
      Citations: 1     
    115. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22045610.
      Citations: 22     Fields:    Translation:Humans
    116. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 109703.
      Citations: 4     Fields:    Translation:Humans
    117. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 221118.
      Citations:    Fields:    Translation:Humans
    118. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 118805.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    119. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 2910423.
      Citations: 34     Fields:    Translation:Humans
    120. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 2809682.
      Citations: 7     Fields:    Translation:Humans
    121. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 6865442.
      Citations: 2     Fields:    Translation:Humans
    122. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 7083209.
      Citations: 4     Fields:    Translation:Humans
    123. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 7273012.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    124. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 7720036.
      Citations: 4     Fields:    Translation:Humans
    125. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 10367172.
      Citations: 5     Fields:    Translation:Humans
    126. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 10920129.
      Citations: 84     Fields:    Translation:Humans
    127. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12006521.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    128. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11078488.
      Citations: 149     Fields:    Translation:HumansCTClinical Trials
    129. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 10776969.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    130. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 10813717.
      Citations: 4     Fields:    Translation:Humans
    131. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11900212.
      Citations: 4     Fields:    Translation:Humans
    132. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15570071.
      Citations: 48     Fields:    Translation:Humans
    133. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12611463.
      Citations: 67     Fields:    Translation:Humans
    134. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 14984485.
      Citations:    Fields:    Translation:Humans
    135. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16270318.
      Citations: 43     Fields:    Translation:Humans
    136. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16299166.
      Citations:    Fields:    Translation:Animals
    137. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15937910.
      Citations: 8     Fields:    Translation:Humans
    138. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16360786.
      Citations: 1131     Fields:    Translation:Humans
    139. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15301567.
      Citations:    Fields:    Translation:Humans
    140. Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS. Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. Clin Cancer Res. 2017 Mar 15; 23(6):1407-1413. PMID: 27852698.
      Citations: 3     Fields:    Translation:Humans
    141. Warner ET, Ballman KV, Strand C, Boughey JC, Buzdar AU, Carey LA, Sikov WM, Partridge AH. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Res Treat. 2016 08; 159(1):109-18. PMID: 27449492.
      Citations: 12     Fields:    Translation:Humans
    142. Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. Eur J Cancer. 2016 Mar; 56:85-92. PMID: 26829011.
      Citations: 3     Fields:    Translation:HumansCells
    143. Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. Eur J Cancer. 2015 Apr; 51(6):685-96. PMID: 25752740.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    144. Ingle JN, Kalari KR, Buzdar AU, Robson ME, Goetz MP, Desta Z, Barman P, Dudenkov TT, Northfelt DW, Perez EA, Flockhart DA, Williard CV, Wang L, Weinshilboum RM. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids. 2015 Jul; 99(Pt A):32-8. PMID: 25163006.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    145. McBride A, Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK, Sahin A, Strom EA, Buzdar A, Valero V, Hortobagyi GN, Hunt KK, Buchholz TA. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8. PMID: 24721590.
      Citations: 32     Fields:    Translation:Humans
    146. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, Ewer MS, Hunt KK. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Dec; 14(13):1317-25. PMID: 24239210.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    147. Buzdar AU. Meta-analysis: selective estrogen-receptor modulators reduce breast cancer incidence. Ann Intern Med. 2013 Sep 17; 159(6):JC9. PMID: 24042392.
      Citations:    Fields:    Translation:Humans
    148. Buzdar AU. Combination endocrine treatments unproven in breast cancer. Lancet Oncol. 2013 Sep; 14(10):917-8. PMID: 23902873.
      Citations:    Fields:    Translation:Humans
    149. Afentakis M, Dowsett M, Sestak I, Salter J, Howell T, Buzdar A, Forbes J, Cuzick J. Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study. Breast Cancer Res Treat. 2013 Jul; 140(2):253-62. PMID: 23852223.
      Citations: 9     Fields:    Translation:Humans
    150. Litton J, Buzdar A, Mac Gregor MC, Gonzalez-Angulo A, Hortobagyi G. Tamoxifen therapy for patients with breast cancer. Lancet. 2013 Jun 15; 381(9883):2077-8. PMID: 23769223.
      Citations: 1     Fields:    Translation:Humans
    151. Kelly CM, Buzdar AU. Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer. Drugs. 2013 May; 73(6):505-15. PMID: 23605692.
      Citations: 7     Fields:    Translation:HumansAnimals
    152. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013 Aug; 24(8):1999-2004. PMID: 23562929.
      Citations: 20     Fields:    Translation:Humans
    153. Liu M, Ingle JN, Fridley BL, Buzdar AU, Robson ME, Kubo M, Wang L, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Goetz MP, Northfelt DW, Perez EA, Williard CV, Schaid DJ, Nakamura Y, Weinshilboum RM. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol. 2013 Apr; 27(4):657-70. PMID: 23518928.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    154. Vachon CM, Suman VJ, Brandt KR, Kosel ML, Buzdar AU, Olson JE, Wu FF, Flickinger LM, Ursin G, Elliott CR, Shepherd L, Weinshilboum RM, Goss PE, Ingle JN. Mammographic breast density response to aromatase inhibition. Clin Cancer Res. 2013 Apr 15; 19(8):2144-53. PMID: 23468058.
      Citations: 15     Fields:    Translation:Humans
    155. Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Jan; 14(1):88-96. PMID: 23234763.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    156. Lyman GH, Burstein HJ, Buzdar AU, D'Agostino R, Ellis PA. Making genuine progress against metastatic breast cancer. J Clin Oncol. 2012 Oct 01; 30(28):3448-51. PMID: 22927527.
      Citations: 2     Fields:    Translation:Humans
    157. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5. PMID: 22331946.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    158. Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Buzdar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C, Robertson JF. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol. 2012 Jun; 23(6):1378-86. PMID: 22317766.
      Citations: 19     Fields:    Translation:Humans
    159. Kelly CM, Buzdar AU. Aromatase inhibitors in premenopausal breast cancer. Lancet Oncol. 2012 Apr; 13(4):320-1. PMID: 22265695.
      Citations:    Fields:    Translation:Humans
    160. Ewer MS, Yang M, Buzdar AU. Screening for cardiac risk before anthracycline administration: what are the real benefits? Clin Breast Cancer. 2012 Feb; 12(1):1-3. PMID: 22130035.
      Citations:    Fields:    Translation:Humans
    161. Arun B, Valero V, Liu D, Brewster A, Green M, Gutierrez-Barrera A, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res (Phila). 2012 Feb; 5(2):276-82. PMID: 22102688.
      Citations:    Fields:    Translation:Humans
    162. Buzdar A, Vogel C, Schwartzberg L, Garin A, Perez A, Ingle J, Houghton M, Zergebel C, Kimball B. Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer. Cancer. 2012 Jul 01; 118(13):3244-53. PMID: 22045595.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    163. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34. PMID: 22042783.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    164. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011 Nov 10; 29(32):4273-8. PMID: 21990413.
      Citations: 223     Fields:    Translation:Humans
    165. Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, Forbes JF, Cuzick J. Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. J Clin Oncol. 2011 Nov 10; 29(32):4266-72. PMID: 21990403.
      Citations: 17     Fields:    Translation:Humans
    166. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC, Park ST, Pusztai L, Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012 May 15; 118(10):2603-14. PMID: 22370716.
      Citations: 101     Fields:    Translation:Humans
    167. Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, Kuerer HM, Hortobagyi GN, Sahin AA, Meric-Bernstam F. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. 2012 May 01; 118(9):2385-93. PMID: 21953213.
      Citations: 18     Fields:    Translation:Humans
    168. Buzdar AU, Xu B, Digumarti R, Goedhals L, Hu X, Semiglazov V, Cheporov S, Gotovkin E, Hoersch S, Rittweger K, Miles DW, O'Shaughnessy J, Tjulandin S. Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. Ann Oncol. 2012 Mar; 23(3):589-597. PMID: 21633047.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    169. Mittendorf EA, Jeruss JS, Tucker SL, Kolli A, Newman LA, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011 May 20; 29(15):1956-62. PMID: 21482989.
      Citations: 28     Fields:    Translation:Humans
    170. Dowsett M, Salter J, Zabaglo L, Mallon E, Howell A, Buzdar AU, Forbes J, Pineda S, Cuzick J. Predictive algorithms for adjuvant therapy: TransATAC. Steroids. 2011 Jul; 76(8):777-80. PMID: 21470560.
      Citations: 9     Fields:    Translation:Humans
    171. Buzdar AU. Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream. Lancet Oncol. 2011 Apr; 12(4):316-8. PMID: 21429798.
      Citations:    Fields:    Translation:Humans
    172. Ferrajoli A, Buzdar AU, Dejesus Y, Cheng L, Michaud LB, Rodriguez MA. Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia. Cancer. 2011 Jul 15; 117(14):3268-75. PMID: 21264831.
      Citations: 4     Fields:    Translation:Humans
    173. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010 Dec; 11(12):1135-41. PMID: 21087898.
      Citations: 266     Fields:    Translation:HumansCTClinical Trials
    174. Kelly CM, Buzdar AU. Anastrozole. Expert Opin Drug Saf. 2010 Nov; 9(6):995-1003. PMID: 20923259.
      Citations: 7     Fields:    Translation:Humans
    175. Mazouni C, Baggerly K, Hawke D, Tsavachidis S, André F, Buzdar AU, Martin PM, Kobayashi R, Pusztai L. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. Proteomics. 2010 Oct; 10(19):3525-32. PMID: 20827732.
      Citations: 6     Fields:    Translation:Humans
    176. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011 Jan 01; 117(1):39-47. PMID: 20740500.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    177. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010 Jul 15; 116(14):3348-56. PMID: 20564075.
      Citations: 143     Fields:    Translation:HumansCTClinical Trials
    178. Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross HT, Babiera GV, Meric-Bernstam F, Hunt KK, Kuerer HM. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010 Jun 15; 116(12):2884-9. PMID: 20564395.
      Citations: 36     Fields:    Translation:Humans
    179. Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res. 2010 Apr 15; 70(8):3278-86. PMID: 20354183.
      Citations: 25     Fields:    Translation:Humans
    180. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL, Shak S. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010 Apr 10; 28(11):1829-34. PMID: 20212256.
      Citations: 227     Fields:    Translation:Humans
    181. Moulder SL, Holmes FA, Tolcher AW, Thall P, Broglio K, Valero V, Buzdar AU, Arbuck SG, Seidman A, Hortobagyi GN. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer. 2010 Feb 15; 116(4):814-21. PMID: 20052721.
      Citations: 6     Fields:    Translation:Humans
    182. Kelly CM, Buzdar AU. Aromatase inhibitors alone or in sequence with tamoxifen - clinical evaluation of the BIG 1-98 trial. Expert Opin Pharmacother. 2010 Feb; 11(3):489-92. PMID: 20053139.
      Citations: 2     Fields:    Translation:CTClinical Trials
    183. Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, Fridley BL, Jenkins GD, Batzler A, Suman VJ, Ravi S, Dixon JM, Miller WR, Wieben ED, Buzdar A, Weinshilboum RM, Ingle JN. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res. 2010 Jan 01; 70(1):319-28. PMID: 20048079.
      Citations: 42     Fields:    Translation:Humans
    184. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010 Jan 20; 28(3):509-18. PMID: 19949017.
      Citations: 238     Fields:    Translation:Humans
    185. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010 Jan 01; 28(1):92-8. PMID: 19933921.
      Citations: 241     Fields:    Translation:Humans
    186. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, Baselga J, Gonzalez-Angulo AM. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009 Dec 01; 15(23):7381-8. PMID: 19920100.
      Citations: 102     Fields:    Translation:HumansCells
    187. Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S. Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain. 2009 Nov; 10(11):1146-50. PMID: 19595634.
      Citations: 29     Fields:    Translation:Humans
    188. Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, Cutuli B, Linforth R, Maass N, Noguchi S, Robidoux A, Verma S, Hadji P. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast. 2009 Aug; 18 Suppl 2:S1-11. PMID: 19712865.
      Citations: 14     Fields:    Translation:HumansPHPublic Health
    189. Buzdar AU. Medical oncology: Endocrine-therapy-related symptoms and breast cancer. Nat Rev Clin Oncol. 2009 Jun; 6(6):309-10. PMID: 19483735.
      Citations: 1     Fields:    Translation:Humans
    190. Buzdar AU. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol. 2009 Jun; 20(6):993-9. PMID: 19150946.
      Citations: 29     Fields:    Translation:HumansCells
    191. Gonzalez-Angulo AM, Walters R, Broglio K, Frye DK, Strom EA, Theriault RL, Booser DJ, Valero V, Buzdar AU, Hortobagyi GN. Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. Clin Breast Cancer. 2008 Dec; 8(6):516-21. PMID: 19073507.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    192. Buzdar AU. Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs Today (Barc). 2008 Sep; 44(9):679-92. PMID: 19137123.
      Citations: 5     Fields:    Translation:Humans
    193. Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, Hortobagyi GN, Brewster AM. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol. 2008 Sep 01; 26(25):4072-7. PMID: 18757321.
      Citations: 63     Fields:    Translation:Humans
    194. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol. 2008 Oct 20; 26(30):4891-8. PMID: 18725649.
      Citations: 71     Fields:    Translation:Humans
    195. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Staging of breast cancer in the neoadjuvant setting. Cancer Res. 2008 Aug 15; 68(16):6477-81. PMID: 18701468.
      Citations: 12     Fields:    Translation:Humans
    196. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20; 100(16):1179-83. PMID: 18695137.
      Citations: 135     Fields:    Translation:Humans
    197. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008 Apr 01; 26(10):1664-70. PMID: 18316794.
      Citations: 133     Fields:    Translation:HumansCTClinical Trials
    198. Buzdar AU. Clinical experience with epothilones in patients with breast cancer. Clin Breast Cancer. 2008 Mar; 8 Suppl 2:S71-8. PMID: 18637402.
      Citations: 3     Fields:    Translation:Humans
    199. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008 Feb 10; 26(5):814-9. PMID: 18258991.
      Citations: 115     Fields:    Translation:Humans
    200. Buzdar AU, Coombes RC, Goss PE, Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer. 2008 Feb 01; 112(3 Suppl):700-709. PMID: 18072256.
      Citations: 16     Fields:    Translation:Humans
    201. Come SE, Buzdar AU, Ingle JN, Johnston SRD, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE. Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. Cancer. 2008 Feb 01; 112(3 Suppl):673-678. PMID: 18072254.
      Citations: 2     Fields:    Translation:Humans
    202. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol. 2008 Mar 01; 26(7):1059-65. PMID: 18227529.
      Citations: 121     Fields:    Translation:Humans
    203. Boughey JC, Buzdar AU, Hunt KK. In brief. Curr Probl Surg. 2008 Jan; 45(1):6-11. PMID: 18206435.
      Citations:    
    204. Boughey JC, Buzdar AU, Hunt KK. Recent advances in the hormonal treatment of breast cancer. Curr Probl Surg. 2008 Jan; 45(1):13-55. PMID: 18206436.
      Citations:    Fields:    Translation:Humans
    205. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008 Jan 10; 26(2):246-52. PMID: 18056680.
      Citations: 44     Fields:    Translation:Humans
    206. Buzdar AU. Preoperative chemotherapy treatment of breast cancer--a review. Cancer. 2007 Dec 01; 110(11):2394-407. PMID: 17941030.
      Citations: 21     Fields:    Translation:Humans
    207. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007 Dec; 18(12):1927-34. PMID: 17998286.
      Citations: 97     Fields:    Translation:Humans
    208. Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, Buzdar AU. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol. 2007 Nov 01; 25(31):4967-73. PMID: 17971595.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    209. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007 Oct 01; 25(28):4414-22. PMID: 17785706.
      Citations: 396     Fields:    Translation:Humans
    210. Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin A, Singletary SE, Buzdar AU, Hortobágyi GN. Trends for inflammatory breast cancer: is survival improving? Oncologist. 2007 Aug; 12(8):904-12. PMID: 17766649.
      Citations: 45     Fields:    Translation:Humans
    211. Buzdar AU. Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer. J Clin Oncol. 2007 May 20; 25(15):2147-8; author reply 2148. PMID: 17513830.
      Citations:    Fields:    Translation:Humans
    212. Buzdar AU. Adjuvant chemotherapy for high-risk operable breast cancer. J Clin Oncol. 2007 May 01; 25(13):1642-4. PMID: 17404366.
      Citations: 2     Fields:    Translation:Humans
    213. Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, Symmans WF, Pusztai L. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res. 2007; 9(6):R87. PMID: 18086299.
      Citations: 14     Fields:    Translation:HumansCells
    214. Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J. 2007 Jan-Feb; 13(1):72-5. PMID: 17214797.
      Citations: 7     Fields:    Translation:Humans
    215. Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, Hunt KK, Whitman GJ, Stephens T, Buzdar AU, Green MC, Symmans WF. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol. 2006 Nov; 13(11):1443-9. PMID: 17028770.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    216. Peintinger F, Symmans WF, Gonzalez-Angulo AM, Boughey JC, Buzdar AU, Yu TK, Hunt KK, Singletary SE, Babiera GV, Lucci A, Meric-Bernstam F, Kuerer HM. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2006 Sep 15; 107(6):1248-54. PMID: 16862596.
      Citations: 9     Fields:    Translation:Humans
    217. Buzdar AU, Guastalla JP, Nabholtz JM, Cuzick J. Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer. 2006 Aug 01; 107(3):472-80. PMID: 16804925.
      Citations: 6     Fields:    Translation:Humans
    218. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006 Aug; 7(8):633-43. PMID: 16887480.
      Citations: 101     Fields:    Translation:Humans
    219. Buchholz TA, Strom EA, Oswald MJ, Perkins GH, Oh J, Domain D, Yu TK, Woodward WA, Tereffe W, Singletary SE, Thomas E, Buzdar AU, Hortobagyi GN, McNeese MD. Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1155-60. PMID: 16750325.
      Citations: 3     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    220. Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer. 2006 Jun 01; 106(11):2327-36. PMID: 16639731.
      Citations: 10     Fields:    Translation:Humans
    221. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer. 2006 May 15; 106(10):2095-103. PMID: 16598749.
      Citations: 86     Fields:    Translation:Humans
    222. Buzdar AU. Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. J Clin Oncol. 2006 Jun 01; 24(16):2409-11. PMID: 16682721.
      Citations: 3     Fields:    Translation:Humans
    223. Buzdar AU. St Gallen guidelines: aromatase inhibitors recommended by name for adjuvant therapy. Ann Oncol. 2006 May; 17(5):878-9. PMID: 16638951.
      Citations:    Fields:    Translation:Humans
    224. Buzdar AU. Update on the management of inflammatory breast cancer. Clin Adv Hematol Oncol. 2006 May; 4(5):344-5. PMID: 16728943.
      Citations:    Fields:    Translation:Humans
    225. Buzdar AU, Baum M, Cuzick J. Letrozole or tamoxifen in early breast cancer. N Engl J Med. 2006 Apr 06; 354(14):1528-30; author reply 1528-30. PMID: 16598051.
      Citations:    Fields:    Translation:Humans
    226. Chlebowski RT. Letrozole or tamoxifen in early breast cancer. N Engl J Med. 2006 Apr 06; 354(14):1528-30; author reply 1528-30. PMID: 16602149.
      Citations:    Fields:    Translation:Humans
    227. Buzdar AU. Dietary modification and risk of breast cancer. JAMA. 2006 Feb 08; 295(6):691-2. PMID: 16467239.
      Citations:    Fields:    Translation:Humans
    228. Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006 Feb; 243(2):257-64. PMID: 16432360.
      Citations: 61     Fields:    Translation:Humans
    229. Kim HJ, Cui X, Hilsenbeck SG, Lee AV. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1013s-1018s. PMID: 16467118.
      Citations: 29     Fields:    Translation:HumansCells
    230. Paik S. Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1019s-1023s. PMID: 16467119.
      Citations: 9     Fields:    Translation:Humans
    231. Ingle JN. Adjuvant endocrine therapy for postmenopausal women with early breast cancer. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1031s-1036s. PMID: 16467121.
      Citations: 6     Fields:    Translation:Humans
    232. Buzdar AU, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1037s-1048s. PMID: 16467122.
      Citations: 4     Fields:    Translation:Humans
    233. Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005 Dec 20; 23(36):9304-11. PMID: 16361629.
      Citations: 90     Fields:    Translation:Humans
    234. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005 Nov 20; 23(33):8331-9. PMID: 16293864.
      Citations: 78     Fields:    Translation:Humans
    235. Buzdar AU, Cuzick J. Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer. J Clin Oncol. 2005 Nov 20; 23(33):8544-6; author reply 8546-7. PMID: 16293888.
      Citations: 1     Fields:    Translation:Humans
    236. Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Pollard S, Clack G, Coibion M, Bianco AR. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod. 2006 Feb; 21(2):545-53. PMID: 16210385.
      Citations: 8     Fields:    Translation:Humans
    237. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005 Oct 01; 23(28):7098-104. PMID: 16192593.
      Citations: 29     Fields:    Translation:Humans
    238. Yamaya H, Yoshida K, Kuritani J, Yonezawa J, Yonezawa JI, Tsuda M, Shindo T, Nagayama S, Buzdar AU. Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose. J Clin Pharm Ther. 2005 Oct; 30(5):459-70. PMID: 16164493.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    239. Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, Yin G, Kau SW, Hortobagyi GN, Rivera E. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer. 2005 Sep 15; 104(6):1158-71. PMID: 16047352.
      Citations: 14     Fields:    Translation:Humans
    240. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005 Sep 01; 23(25):5983-92. PMID: 16087943.
      Citations: 94     Fields:    Translation:HumansCTClinical Trials
    241. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Buchholz TA. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jun 01; 62(2):351-7. PMID: 15890574.
      Citations: 32     Fields:    Translation:Humans
    242. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 01; 23(16):3676-85. PMID: 15738535.
      Citations: 288     Fields:    Translation:HumansCTClinical Trials
    243. Howell A, Buzdar A. Are aromatase inhibitors superior to antiestrogens? J Steroid Biochem Mol Biol. 2005 Feb; 93(2-5):237-47. PMID: 15860266.
      Citations: 6     Fields:    Translation:Humans
    244. Ingle JN. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):900s-5s. PMID: 15701884.
      Citations: 9     Fields:    Translation:Humans
    245. Lønning PE. Exemestane for breast cancer prevention: a feasible strategy? Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):918s-24s. PMID: 15701887.
      Citations: 1     Fields:    Translation:Humans
    246. Johnston SR. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):889s-99s. PMID: 15701883.
      Citations: 13     Fields:    Translation:HumansCells
    247. Anderson WF, Devesa SS. Breast carcinoma in men. Cancer. 2005 Jan 15; 103(2):432-3; author reply 433. PMID: 15578682.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    248. Yue W, Wang JP, Li Y, Bocchinfuso WP, Korach KS, Devanesan PD, Rogan E, Cavalieri E, Santen RJ. Tamoxifen versus aromatase inhibitors for breast cancer prevention. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):925s-30s. PMID: 15701888.
      Citations: 16     Fields:    Translation:HumansAnimals
    249. Yamamoto Y, Shibata J, Yonekura K, Sato K, Hashimoto A, Aoyagi Y, Wierzba K, Yano S, Asao T, Buzdar AU, Terada T. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. Clin Cancer Res. 2005 Jan 01; 11(1):315-22. PMID: 15671561.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    250. Buzdar AU. Aromatase inhibitors: changing the face of endocrine therapy for breast cancer. Breast Dis. 2005-2006; 24:107-17. PMID: 16917143.
      Citations: 3     Fields:    Translation:Humans
    251. Buzdar A, Macahilig C. How rapidly do oncologists respond to clinical trial data? Oncologist. 2005 Jan; 10(1):15-21. PMID: 15632249.
      Citations: 4     Fields:    Translation:Humans
    252. Yu TK, Whitman GJ, Thames HD, Buzdar AU, Strom EA, Perkins GH, Schechter NR, McNeese MD, Kau SW, Thomas ES, Hortobagyi GN, Buchholz TA. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst. 2004 Nov 17; 96(22):1676-81. PMID: 15547180.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    253. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, Broglio KR, Smith TL, Hortobagyi GN. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer. 2004 Oct 15; 101(8):1760-6. PMID: 15386311.
      Citations: 22     Fields:    Translation:Humans
    254. Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, Buzdar AU, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer. 2004 Oct 01; 101(7):1508-13. PMID: 15378497.
      Citations: 7     Fields:    Translation:Humans
    255. Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach. Cancer. 2004 Oct 01; 101(7):1482-9. PMID: 15378476.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    256. Buzdar AU. Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs Today (Barc). 2004 Sep; 40(9):751-64. PMID: 15538548.
      Citations: 2     Fields:    Translation:HumansAnimals
    257. Buzdar AU. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update. Clin Breast Cancer. 2004 Sep; 5 Suppl 1:S6-S12. PMID: 15347433.
      Citations: 6     Fields:    Translation:Humans
    258. Buzdar AU. Current developments in hormonal therapy of breast cancer. Clin Breast Cancer. 2004 Sep; 5 Suppl 1:S4-5. PMID: 15347432.
      Citations:    Fields:    Translation:Humans
    259. Resetkova E, Gonzalez-Angulo AM, Sneige N, Mcdonnell TJ, Buzdar AU, Kau SW, Yamamura Y, Reuben JM, Hortobagyi GN, Cristofanilli M. Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer. 2004 Sep 01; 101(5):913-7. PMID: 15329897.
      Citations: 3     Fields:    Translation:HumansCells
    260. Blakely LJ, Buzdar A, Chang HY, Frye D, Theriault R, Valero V, Rivera E, Booser D, Kuritani J, Tsuda M. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5425-31. PMID: 15328180.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    261. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer. 2004 Aug 01; 101(3):466-75. PMID: 15274059.
      Citations: 94     Fields:    Translation:Humans
    262. Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1337-42. PMID: 15275718.
      Citations: 9     Fields:    Translation:Humans
    263. Buzdar AU. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol. 2004 Aug 01; 22(15):3199-200; author reply 3200-1. PMID: 15284276.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    264. Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer. 2004 Jun 15; 100(12):2512-32. PMID: 15197792.
      Citations: 21     Fields:    
    265. Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004 Jun 15; 22(12):2294-302. PMID: 15197190.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    266. Buzdar AU, Vergote I, Sainsbury R. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women. Breast J. 2004 May-Jun; 10(3):211-7. PMID: 15125747.
      Citations: 4     Fields:    Translation:Humans
    267. Garg AK, Strom EA, McNeese MD, Buzdar AU, Hortobagyi GN, Kuerer HM, Perkins GH, Singletary SE, Hunt KK, Sahin A, Schechter N, Valero V, Tucker SL, Buchholz TA. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):138-45. PMID: 15093909.
      Citations: 12     Fields:    Translation:Humans
    268. Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M, Forbes J, Guastalla JP, Houghton J, Williams N, Howell A, Locker G, MacKey J, Sainsbury R, Tobias J. Adjuvant use of anastrozole in breast cancer. J Clin Oncol. 2004 Apr 15; 22(8):1524-6; author reply 1526-7. PMID: 15084628.
      Citations: 1     Fields:    Translation:Humans
    269. Buzdar AU. Preoperative chemotherapy for breast cancer. Clin Adv Hematol Oncol. 2004 Apr; 2(4):212, 215. PMID: 16163183.
      Citations:    Fields:    Translation:Humans
    270. Buzdar AU. Letrozole in breast cancer. N Engl J Med. 2004 Feb 12; 350(7):727-30; author reply 727-30. PMID: 14960751.
      Citations: 1     Fields:    Translation:Humans
    271. Blakely LJ, Buzdar AU, Lozada JA, Shullaih SA, Hoy E, Smith TL, Hortobagyi GN. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer. 2004 Feb 01; 100(3):465-9. PMID: 14745861.
      Citations: 35     Fields:    Translation:Humans
    272. Buzdar AU. Paclitaxel in early breast cancer: a viewpoint by Aman U. Buzdar. Drugs. 2004; 64(16):1848-9. PMID: 15301566.
      Citations:    Fields:    Translation:Humans
    273. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004 Jan 01; 100(1):44-52. PMID: 14692023.
      Citations: 128     Fields:    Translation:Humans
    274. Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS. Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):327S-330S. PMID: 14734487.
      Citations: 1     Fields:    Translation:HumansCells
    275. Ellis MJ. Neoadjuvant endocrine therapy as a drug development strategy. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):391S-5S. PMID: 14734497.
      Citations: 3     Fields:    Translation:HumansCells
    276. Buzdar AU. Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):355S-61S. PMID: 14734491.
      Citations: 5     Fields:    Translation:Humans
    277. Baum M, Buzdar A, Howell A. ATAC trial did not report interim results. BMJ. 2003 Nov 01; 327(7422):1050. PMID: 14593064.
      Citations:    Fields:    Translation:Humans
    278. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003 Nov 01; 98(9):1802-10. PMID: 14584060.
      Citations: 158     Fields:    Translation:HumansCTClinical Trials
    279. Thürlimann B, Robertson JF, Nabholtz JM, Buzdar A, Bonneterre J. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer. 2003 Nov; 39(16):2310-7. PMID: 14556922.
      Citations: 8     Fields:    Translation:Humans
    280. Simons WR, Jones D, Buzdar A. Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. Clin Ther. 2003 Nov; 25(11):2972-87. PMID: 14693319.
      Citations: 4     Fields:    Translation:Humans
    281. Buzdar AU. Breast cancer in men. Oncology (Williston Park). 2003 Oct; 17(10):1361-4; discussion 1364, 1369-72. PMID: 14606362.
      Citations: 4     Fields:    Translation:Humans
    282. Buzdar AU. Role of anastrozole in adjuvant therapy for postmenopausal patients. Semin Oncol. 2003 Oct; 30(5 Suppl 16):21-9. PMID: 14613023.
      Citations: 1     Fields:    Translation:Humans
    283. Woodward WA, Strom EA, Tucker SL, Katz A, McNeese MD, Perkins GH, Buzdar AU, Hortobagyi GN, Hunt KK, Sahin A, Meric F, Sneige N, Buchholz TA. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):336-44. PMID: 12957243.
      Citations: 21     Fields:    Translation:Humans
    284. Woodward WA, Strom EA, McNeese MD, Perkins GH, Outlaw EL, Hortobagyi GN, Buzdar AU, Buchholz TA. Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):327-35. PMID: 12957242.
      Citations: 10     Fields:    Translation:Humans
    285. Buzdar AU, Hortobagyi GN. Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer. Cancer Treat Rev. 2003 Oct; 29(5):449-52. PMID: 12972364.
      Citations:    Fields:    Translation:Humans
    286. Buzdar AU. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview. J Steroid Biochem Mol Biol. 2003 Sep; 86(3-5):399-403. PMID: 14623537.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    287. Baum M, Buzdar A. The current status of aromatase inhibitors in the management of breast cancer. Surg Clin North Am. 2003 Aug; 83(4):973-94. PMID: 12875605.
      Citations: 3     Fields:    Translation:Humans
    288. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003 Jul 15; 98(2):229-38. PMID: 12872340.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    289. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003 Jun 15; 97(12):2960-71. PMID: 12784330.
      Citations: 44     Fields:    Translation:Humans
    290. Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003 Jun 01; 97(11):2716-23. PMID: 12767083.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    291. Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer. 2003 Apr 01; 97(7):1758-65. PMID: 12655533.
      Citations: 17     Fields:    Translation:Humans
    292. Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE, Jones SE, Munster PN, Peterson P, Melemed AS, Winer E, Hudis C. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):1007-14. PMID: 12637464.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    293. Buzdar AU. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):468S-72S. PMID: 12538502.
      Citations: 8     Fields:    Translation:Humans
    294. Cristofanilli M, Buzdar AU, Hortobágyi GN. Update on the management of inflammatory breast cancer. Oncologist. 2003; 8(2):141-8. PMID: 12697939.
      Citations: 29     Fields:    Translation:Humans
    295. Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):443S-6S. PMID: 12538498.
      Citations: 1     Fields:    Translation:Humans
    296. Buzdar AU. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen. Expert Rev Anticancer Ther. 2002 Dec; 2(6):623-9. PMID: 12503208.
      Citations: 2     Fields:    Translation:Humans
    297. Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res. 2002 Nov; 8(11):3360-8. PMID: 12429622.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    298. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002 Nov 01; 95(9):2006-16. PMID: 12404296.
      Citations: 42     Fields:    Translation:Humans
    299. Buzdar AU. New generation aromatase inhibitors--from the advanced to the adjuvant setting. Breast Cancer Res Treat. 2002 Oct; 75 Suppl 1:S13-7; discussion S33-5. PMID: 12353818.
      Citations: 4     Fields:    Translation:Humans
    300. Valero V, Buzdar AU, McNeese M, Singletary E, Hortobagyi GN. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2002 Oct; 3 Suppl 2:S63-8. PMID: 12435294.
      Citations: 9     Fields:    Translation:Humans
    301. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15; 20(16):3386-95. PMID: 12177098.
      Citations: 113     Fields:    Translation:HumansCTClinical Trials
    302. Huang E, McNeese MD, Strom EA, Perkins GH, Katz A, Hortobagyi GN, Valero V, Kuerer HM, Singletary SE, Hunt KK, Buzdar AU, Buchholz TA. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1225-33. PMID: 12128124.
      Citations: 11     Fields:    Translation:Humans
    303. Buchholz TA, Katz A, Strom EA, McNeese MD, Perkins GH, Hortobagyi GN, Thames HD, Kuerer HM, Singletary SE, Sahin AA, Hunt KK, Buzdar AU, Valero V, Sneige N, Tucker SL. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2002 Jul 15; 53(4):880-8. PMID: 12095553.
      Citations: 13     Fields:    Translation:Humans
    304. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002 Jun 22; 359(9324):2131-9. PMID: 12090977.
      Citations: 370     Fields:    Translation:HumansCTClinical Trials
    305. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol. 2002 Jun; 25(3):235-7. PMID: 12040279.
      Citations: 14     Fields:    Translation:Humans
    306. Assikis VJ, Buzdar A. Recent advances in aromatase inhibitor therapy for breast cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 11):120-8. PMID: 12138406.
      Citations:    Fields:    Translation:Humans
    307. Newman LA, Buzdar AU, Singletary SE, Kuerer HM, Buchholz T, Ames FC, Ross MI, Hunt KK. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol. 2002 Apr; 9(3):228-34. PMID: 11923128.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    308. Buzdar AU. Superior efficacy of letrozole versus tamoxifen as first-line therapy. J Clin Oncol. 2002 Feb 01; 20(3):876-8. PMID: 11821477.
      Citations:    Fields:    Translation:Humans
    309. Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J. 2002 Jan-Feb; 8(1):2-9. PMID: 11856154.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    310. Buchholz TA, Tucker SL, Masullo L, Kuerer HM, Erwin J, Salas J, Frye D, Strom EA, McNeese MD, Perkins G, Katz A, Singletary SE, Hunt KK, Buzdar AU, Hortobagyi GN. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 2002 Jan 01; 20(1):17-23. PMID: 11773149.
      Citations: 26     Fields:    Translation:Humans
    311. Buzdar AU, Come SE, Brodie A, Ellis M, Goss PE, Ingle JN, Johnston SR, Lee AV, Osborne CK, Vogel VG, Hart CS. Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4335s-4337s; discussion 4411s-4412s. PMID: 11916221.
      Citations:    Fields:    Translation:Humans
    312. Mackey JR, Joy AA. Letrozole in second-line therapy of advanced breast cancer: more questions than answers. J Clin Oncol. 2001 Dec 01; 19(23):4353-5. PMID: 11731524.
      Citations:    Fields:    Translation:Humans
    313. Johnson PE, Buzdar A. Are differences in the available aromatase inhibitors and inactivators significant? Clin Cancer Res. 2001 Dec; 7(12 Suppl):4360s-4368s; discussion 4411s-4412s. PMID: 11916226.
      Citations:    Fields:    Translation:Humans
    314. Vogel VG. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PMID: 11916233.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    315. Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, Ross MI, Pusztai L, Hortobagyi GN, Hunt KK. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg. 2001 Dec; 182(6):601-8. PMID: 11839324.
      Citations: 15     Fields:    Translation:Humans
    316. Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL, Buzdar AU, Hortobagyi GN, Theriault RL. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer. 2001 Nov 15; 92(10):2523-8. PMID: 11745185.
      Citations: 50     Fields:    Translation:Humans
    317. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001 Nov 01; 92(9):2247-58. PMID: 11745278.
      Citations: 94     Fields:    Translation:HumansCTClinical Trials
    318. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001 Oct 01; 92(7):1759-68. PMID: 11745247.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    319. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 01; 92(7):1775-82. PMID: 11745249.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    320. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res. 2001 Sep; 7(9):2620-35. PMID: 11555572.
      Citations: 21     Fields:    Translation:Humans
    321. Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J. 2001 Sep-Oct; 7(5):413-20. PMID: 11693900.
      Citations: 13     Fields:    Translation:Humans
    322. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001 Jul 15; 19(14):3357-66. PMID: 11454883.
      Citations: 62     Fields:    Translation:HumansCTClinical Trials
    323. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol. 2001 Jun; 28(3):291-304. PMID: 11402439.
      Citations: 22     Fields:    Translation:Humans
    324. Vlastos G, Jean ME, Mirza AN, Mirza NQ, Kuerer HM, Ames FC, Hunt KK, Ross MI, Buchholz TA, Buzdar AU, Singletary SE. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001 Jun; 8(5):425-31. PMID: 11407517.
      Citations: 23     Fields:    Translation:Humans
    325. Kuerer HM, Buzdar AU, Singletary SE. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast. J Surg Oncol. 2001 Jun; 77(2):139-47. PMID: 11398169.
      Citations: 3     Fields:    Translation:Humans
    326. Copur MS, Ledakis P, Bolton M, Norvell M, Muhvic J. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? J Clin Oncol. 2001 May 01; 19(9):2578; author reply 2580-2. PMID: 11331343.
      Citations: 1     Fields:    Translation:Humans
    327. Buchholz TA, Tucker SL, Erwin J, Mathur D, Strom EA, McNeese MD, Hortobagyi GN, Cristofanilli M, Esteva FJ, Newman L, Singletary SE, Buzdar AU, Hunt KK. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol. 2001 Apr 15; 19(8):2240-6. PMID: 11304777.
      Citations: 13     Fields:    Translation:Humans
    328. Newman LA, Kuerer HM, Fornage B, Mirza N, Hunt KK, Ross MI, Ames FC, Buzdar AU, Singletary SE. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg. 2001 Apr; 181(4):313-8. PMID: 11438265.
      Citations: 5     Fields:    Translation:Humans
    329. Ibrahim NK, Buzdar AU, Valero V, Dhingra K, Willey J, Hortobagyi GN. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer. 2001 Feb 15; 91(4):664-71. PMID: 11241232.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    330. Brito RA, Valero V, Buzdar AU, Booser DJ, Ames F, Strom E, Ross M, Theriault RL, Frye D, Kau SW, Asmar L, McNeese M, Singletary SE, Hortobagyi GN. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 2001 Feb 01; 19(3):628-33. PMID: 11157012.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    331. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res. 2001; 7(3):171-7. PMID: 11692142.
      Citations: 20     Fields:    Translation:HumansCells
    332. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66. PMID: 11458813.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    333. Michaud LB, Jones KL, Buzdar AU. Combination endocrine therapy in the management of breast cancer. Oncologist. 2001; 6(6):538-46. PMID: 11743215.
      Citations: 5     Fields:    Translation:Humans
    334. Ibrahim NK, Buzdar AU, Asmar L, Theriault RL, Hortobagyi GN. Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann Oncol. 2000 Dec; 11(12):1597-601. PMID: 11205469.
      Citations: 7     Fields:    Translation:Humans
    335. Rivera E, Holmes FA, Frye D, Valero V, Theriault RL, Booser D, Walters R, Buzdar AU, Dhingra K, Fraschini G, Hortobagyi GN. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer. 2000 Dec 01; 89(11):2195-201. PMID: 11147589.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    336. Chang S, Alderfer JR, Asmar L, Buzdar AU. Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat. 2000 Nov; 64(2):157-63. PMID: 11194451.
      Citations: 18     Fields:    Translation:Humans
    337. Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, Delpassand ES, House R, Ames FC, Feig BW, Ross MI, Singletary SE, Buzdar AU, Hortobagyi GN, Hunt KK. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000 Oct 15; 18(20):3480-6. PMID: 11032588.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    338. Buzdar AU. Tamoxifen's clinical applications: old and new. Arch Fam Med. 2000 Sep-Oct; 9(9):906-12. PMID: 11031399.
      Citations: 2     Fields:    Translation:Humans
    339. Buzdar A. An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer. Eur J Cancer. 2000 Sep; 36 Suppl 4:S82-4. PMID: 11056331.
      Citations: 1     Fields:    Translation:Humans
    340. Vlastos G, Rubio IT, Mirza NQ, Newman LA, Aurora R, Alderfer J, Buzdar AU, Singletary SE. Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. Ann Surg Oncol. 2000 Sep; 7(8):581-7. PMID: 11005556.
      Citations: 18     Fields:    Translation:Humans
    341. Buzdar A. Exemestane in advanced breast cancer. Anticancer Drugs. 2000 Sep; 11(8):609-16. PMID: 11081451.
      Citations: 1     Fields:    Translation:Humans
    342. Liao Z, Strom EA, Buzdar AU, Singletary SE, Hunt K, Allen PK, McNeese MD. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000 Jul 15; 47(5):1191-200. PMID: 10889372.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    343. Newman LA, Kuerer HM, Hunt KK, Ames FC, Ross MI, Feig BW, Hortobagyi GN, Buzdar AU, Singletary SE. Response to Induction Chemotherapy in Black and White Patients with Locally Advanced Breast Cancer. Breast J. 2000 Jul; 6(4):242-246. PMID: 11348372.
      Citations: 2     Fields:    
    344. Meric F, Mirza NQ, Buzdar AU, Hunt KK, Ames FC, Ross MI, Pollock RE, Newman LA, Feig BW, Strom EA, Buchholz TA, McNeese MD, Hortobagyi GN, Singletary SE. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol. 2000 Jul; 7(6):435-40. PMID: 10894139.
      Citations: 4     Fields:    Translation:Humans
    345. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol. 2000 Jun; 23(3):319-21. PMID: 10857902.
      Citations: 11     Fields:    Translation:Humans
    346. Buzdar AU, Chaudri HA, Trunet PF. Letrozole: which dose to be used? J Clin Oncol. 2000 Apr; 18(8):1802-3. PMID: 10764444.
      Citations:    Fields:    Translation:Humans
    347. Mavligit GM, Estrov Z. CA 125: a clinically useful tumor marker in the management of colorectal carcinoma metastatic to the liver in patients with normal carcinoembryonic antigen. Am J Clin Oncol. 2000 Apr; 23(2):213-5. PMID: 10776987.
      Citations: 3     Fields:    Translation:Humans
    348. Vlastos G, Mirza NQ, Lenert JT, Hunt KK, Ames FC, Feig BW, Ross MI, Buzdar AU, Singletary SE. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer. 2000 Mar 15; 88(6):1417-24. PMID: 10717625.
      Citations: 10     Fields:    Translation:Humans
    349. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000 Feb 02; 92(3):225-33. PMID: 10655439.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    350. Kushwaha AC, Whitman GJ, Stelling CB, Cristofanilli M, Buzdar AU. Primary inflammatory carcinoma of the breast: retrospective review of mammographic findings. AJR Am J Roentgenol. 2000 Feb; 174(2):535-8. PMID: 10658737.
      Citations: 5     Fields:    Translation:Humans
    351. Gale RP, Park RE, Dubois R, Bitran JD, Buzdar A, Hortobagyi G, Jones SE, Lazar GS, Spitzer G, Swain SM, Vaughn CB, Vogel CE, Martino S. Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clin Transplant. 2000 Feb; 14(1):32-41. PMID: 10693633.
      Citations: 7     Fields:    Translation:Humans
    352. Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, Buzdar AU, Hortobagyi GN. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000 Jan 22; 355(9200):281-3. PMID: 10675076.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    353. Lenert JT, Vlastos G, Mirza NQ, Winchester DJ, Binkley SM, Ames FC, Ross MI, Feig BW, Hunt KK, Strom E, Buzdar AU, Hortobagyi GN, Singletary SE. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol. 1999 Dec; 6(8):762-7. PMID: 10622504.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    354. Bland KI, Buzdar AU. Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer. Ann Surg Oncol. 1999 Dec; 6(8 Suppl):12S-13S. PMID: 10619454.
      Citations:    Fields:    Translation:Humans
    355. Robertson JF, Howell A, Buzdar A, von Euler M, Lee D. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. Breast Cancer Res Treat. 1999 Nov; 58(2):157-62. PMID: 10674881.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    356. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov; 17(11):3412-7. PMID: 10550135.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    357. Michaud LB, Buzdar AU. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Drug Saf. 1999 Oct; 21(4):297-309. PMID: 10514021.
      Citations: 5     Fields:    Translation:Humans
    358. Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL, Bast R, Hortobagyi GN. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer. 1999 Oct 01; 86(7):1251-7. PMID: 10506711.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    359. Buzdar AU, Hortobagyi GN. Recent advances in adjuvant therapy of breast cancer. Semin Oncol. 1999 Aug; 26(4 Suppl 12):21-7. PMID: 10482191.
      Citations: 1     Fields:    Translation:Humans
    360. Hortobagyi GN, Hung MC, Buzdar AU. Recent developments in breast cancer therapy. Semin Oncol. 1999 Aug; 26(4 Suppl 12):11-20. PMID: 10482190.
      Citations: 4     Fields:    Translation:Humans
    361. Kuerer HM, Sahin AA, Hunt KK, Newman LA, Breslin TM, Ames FC, Ross MI, Buzdar AU, Hortobagyi GN, Singletary SE. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999 Jul; 230(1):72-8. PMID: 10400039.
      Citations: 63     Fields:    Translation:HumansCTClinical Trials
    362. Buzdar AU. Role of aromatase inhibitors in advanced breast cancer. Endocr Relat Cancer. 1999 Jun; 6(2):219-25. PMID: 10731112.
      Citations: 4     Fields:    Translation:Humans
    363. Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999 May; 17(5):1425-34. PMID: 10334527.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    364. Knoche AJ, Michaud LB, Buzdar AU. Efficacy of Anastrozole in a Consecutive Series of Advanced Breast Cancer Patients Treated with Multiple Prior Chemotherapies and Endocrine Agents: M. D. Anderson Cancer Center Experience. Breast J. 1999 May; 5(3):176-181. PMID: 11348281.
      Citations: 1     Fields:    
    365. Cristofanilli M, Holmes FA, Esparza L, Valero V, Buzdar AU, Neidhart JA, Hortobagyi GN. Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Breast Cancer Res Treat. 1999 Apr; 54(3):225-33. PMID: 10445421.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    366. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol. 1999 Apr; 10(4):403-11. PMID: 10370782.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    367. Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, Buzdar AU, Hortobagyi GN. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol. 1999 Mar; 17(3):855-61. PMID: 10071276.
      Citations: 38     Fields:    Translation:Humans
    368. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999 Feb; 17(2):460-9. PMID: 10080586.
      Citations: 323     Fields:    Translation:HumansCTClinical Trials
    369. Buzdar AU, Hortobagyi GN. Breast cancer. Cancer Chemother Biol Response Modif. 1999; 18:435-69. PMID: 10800497.
      Citations:    Fields:    Translation:Humans
    370. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer. 1999 Jan 01; 85(1):104-11. PMID: 9921981.
      Citations: 25     Fields:    Translation:Humans
    371. Kuerer HM, Newman LA, Buzdar AU, Hunt KK, Dhingra K, Buchholz TA, Binkley SM, Ames FC, Feig BW, Ross MI, Hortobagyi GN, Singletary SE. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998 Dec; 176(6):502-9. PMID: 9926779.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    372. Kuerer HM, Newman LA, Fornage BD, Dhingra K, Hunt KK, Buzdar AU, Ames FC, Ross MI, Feig BW, Hortobagyi GN, Singletary SE. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol. 1998 Dec; 5(8):673-80. PMID: 9869512.
      Citations: 11     Fields:    Translation:Humans
    373. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer. 1998 Sep 15; 83(6):1142-52. PMID: 9740079.
      Citations: 63     Fields:    Translation:HumansCTClinical Trials
    374. Buzdar A. The place of chemotherapy in the treatment of early breast cancer. Br J Cancer. 1998 Sep; 78 Suppl 4:16-20. PMID: 9741784.
      Citations: 5     Fields:    Translation:Humans
    375. Rahman ZU, Hortobagyi GN, Buzdar AU, Champlin R. High-dose chemotherapy with autologous stem cell support in patients with breast cancer. Cancer Treat Rev. 1998 Aug; 24(4):249-63. PMID: 9805506.
      Citations:    Fields:    Translation:Humans
    376. Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer. 1998 Jun 15; 82(12):2366-72. PMID: 9635529.
      Citations: 62     Fields:    Translation:Humans
    377. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998 May 16; 351(9114):1451-67. PMID: 9605801.
      Citations: 712     Fields:    Translation:Humans
    378. Williams GM. Differences in toxicity findings for antiestrogens. J Clin Oncol. 1998 May; 16(5):1999-2000. PMID: 9586922.
      Citations:    Fields:    Translation:Humans
    379. Diaz-Canton EA, Valero V, Rahman Z, Rodriguez-Monge E, Frye D, Smith T, Buzdar AU, Hortobagyi GN. Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. Ann Oncol. 1998 Apr; 9(4):413-8. PMID: 9636832.
      Citations: 7     Fields:    Translation:Humans
    380. Adkins DR, Brown RA, DiPersio JF. Patient selection in high-dose trials of breast cancer. J Clin Oncol. 1998 Mar; 16(3):1238-9. PMID: 9508217.
      Citations:    Fields:    Translation:Humans
    381. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res. 1998 Mar; 4(3):527-34. PMID: 9533518.
      Citations: 12     Fields:    Translation:Humans
    382. Buzdar AU, Hortobagyi GN. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol. 1998 Jan; 16(1):348-53. PMID: 9440763.
      Citations: 13     Fields:    Translation:HumansAnimals
    383. Hortobagyi GN, Buzdar AU. Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management. Cancer Invest. 1998; 16(6):385-90. PMID: 9679529.
      Citations: 2     Fields:    Translation:Humans
    384. Kinney AY, Sahin A, Vernon SW, Frankowski RF, Annegers JF, Hortobagyi GN, Buzdar AU, Frye DK, Dhingra K. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer. 1997 Dec 15; 80(12):2240-9. PMID: 9404700.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    385. Roseman BJ, Buzdar AU, Singletary SE. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. J Surg Oncol. 1997 Nov; 66(3):215-20. PMID: 9369969.
      Citations: 2     Fields:    Translation:Humans
    386. Hortobagyi GN, Willey J, Rahman Z, Holmes FA, Theriault RL, Buzdar AU. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol. 1997 Oct; 24(5 Suppl 17):S17-65-S17-68. PMID: 9374097.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    387. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 1997 Oct; 15(10):3171-7. PMID: 9336352.
      Citations: 6     Fields:    Translation:Humans
    388. Fleming RY, Asmar L, Buzdar AU, McNeese MD, Ames FC, Ross MI, Singletary SE. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol. 1997 Sep; 4(6):452-61. PMID: 9309333.
      Citations: 17     Fields:    Translation:Humans
    389. Herrada J, Iyer RB, Atkinson EN, Sneige N, Buzdar AU, Hortobagyi GN. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res. 1997 Sep; 3(9):1565-9. PMID: 9815844.
      Citations: 33     Fields:    Translation:Humans
    390. Buzdar AU, Asmar L, Hortobagyi GN. Impact of patient characteristics on treatment outcome: anthracycline resistance. Eur J Cancer. 1997 Aug; 33 Suppl 7:S3-6. PMID: 9486095.
      Citations:    Fields:    Translation:Humans
    391. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer. 1997 Feb 15; 79(4):730-9. PMID: 9024711.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    392. Hortobagyi GN, Holmes FA, Ibrahim N, Champlin R, Buzdar AU. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 3):S30-3. PMID: 9071338.
      Citations:    Fields:    Translation:Humans
    393. Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997; 40(4):321-9. PMID: 9225950.
      Citations: 56     Fields:    Translation:Humans
    394. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996 Oct; 14(10):2713-21. PMID: 8874332.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    395. Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M, Hortobagyi GN. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 1996 Oct; 14(10):2722-30. PMID: 8874333.
      Citations: 18     Fields:    Translation:Humans
    396. Inoue T, Kim EE, Wallace S, Yang DJ, Wong FC, Bassa P, Cherif A, Delpassand E, Buzdar A, Podoloff DA. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm. 1996 Aug; 11(4):235-45. PMID: 10851543.
      Citations: 11     Fields:    Translation:Humans
    397. Buzdar AU, Plourde PV, Hortobagyi GN. Aromatase inhibitors in metastatic breast cancer. Semin Oncol. 1996 Aug; 23(4 Suppl 9):28-32. PMID: 8824462.
      Citations: 1     Fields:    Translation:Humans
    398. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996 Jul; 14(7):2000-11. PMID: 8683230.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    399. Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, Mulagha M, Cooper J. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996 Jun 15; 77(12):2503-13. PMID: 8640699.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    400. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ, Wong WH, Hicks KW, Buzdar AU, Podoloff DA. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med. 1996 Jun; 37(6):931-8. PMID: 8683314.
      Citations: 25     Fields:    Translation:Humans
    401. Payne JY, Holmes F, Cohen PR, Gagel R, Buzdar A, Dhingra K. Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia. South Med J. 1996 May; 89(5):542-5. PMID: 8638189.
      Citations: 7     Fields:    Translation:Humans
    402. Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med. 1996 Apr 22; 156(8):882-8. PMID: 8774207.
      Citations: 11     Fields:    Translation:Humans
    403. Hunt KK, Ames FC, Singletary SE, Buzdar AU, Hortobagyi GN. Locally advanced noninflammatory breast cancer. Surg Clin North Am. 1996 Apr; 76(2):393-410. PMID: 8610271.
      Citations: 5     Fields:    Translation:Humans
    404. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995 Dec; 13(12):2886-94. PMID: 8523051.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    405. Ibrahim NK, Buzdar AU. Aromatase inhibitors: current status. Am J Clin Oncol. 1995 Oct; 18(5):407-17. PMID: 7572758.
      Citations: 1     Fields:    Translation:HumansAnimals
    406. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995 Oct; 4(4):715-34. PMID: 8535907.
      Citations: 18     Fields:    Translation:Humans
    407. Hortobagyi GN, Buzdar AU. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J Clin. 1995 Jul-Aug; 45(4):199-226. PMID: 7600278.
      Citations: 8     Fields:    Translation:Humans
    408. Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Clin Cancer Res. 1995 Jul; 1(7):691-7. PMID: 9816034.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    409. Buzdar AU, Holmes FA, Hortobagyi GN. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. Semin Oncol. 1995 Jun; 22(3 Suppl 6):101-4. PMID: 7541151.
      Citations: 3     Fields:    Translation:Humans
    410. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995 Feb; 13(2):513-29. PMID: 7844613.
      Citations: 74     Fields:    Translation:Humans
    411. Hortobagyi GN, Holmes FA, Theriault RL, Buzdar AU. Use of Taxol (paclitaxel) in breast cancer. Oncology. 1994 Oct; 51 Suppl 1:29-32. PMID: 7970507.
      Citations: 5     Fields:    Translation:Humans
    412. Mondzac AM. Tamoxifen dosage and bioequivalence: a correction. J Clin Oncol. 1994 Sep; 12(9):1993-4. PMID: 8083720.
      Citations:    Fields:    Translation:Humans
    413. Dunphy FR, Spitzer G, Fornoff JE, Yau JC, Huan SD, Dicke KA, Buzdar AU, Hortobagyi GN. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer. 1994 Apr 15; 73(8):2157-67. PMID: 8156520.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    414. Yang DJ, Li C, Kuang LR, Price JE, Buzdar AU, Tansey W, Cherif A, Gretzer M, Kim EE, Wallace S. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci. 1994; 55(1):53-67. PMID: 8015349.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    415. Buzdar AU, Kau S, Hortobagyi GN, Theriault RL, Booser D, Holmes FA, Walters R, Krakoff IH. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1994; 33(4):313-6. PMID: 8281625.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    416. Buzdar AU, Hortobagyi GN, Frye D, Ho D, Booser DJ, Valero V, Holmes FA, Birmingham BK, Bui K, Yeh C, et al. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol. 1994 Jan; 12(1):50-4. PMID: 8270984.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    417. Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med. 1994 Jan 01; 120(1):18-25. PMID: 8250452.
      Citations: 35     Fields:    Translation:Humans
    418. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MB, Kelley S, Tepper M, Greene D, Booser D, Buzdar A, et al. Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study. Adv Exp Med Biol. 1994; 353:193-202. PMID: 7985538.
      Citations: 1     Fields:    Translation:HumansAnimalsCTClinical Trials
    419. Cohen PR, Buzdar AU. Metastatic breast carcinoma mimicking an acute paronychia of the great toe: case report and review of subungual metastases. Am J Clin Oncol. 1993 Feb; 16(1):86-91. PMID: 8424412.
      Citations: 1     Fields:    Translation:Humans
    420. Hortobágyi GN, Buzdar AU. Present status of anthracyclines in the adjuvant treatment of breast cancer. Drugs. 1993; 45 Suppl 2:10-9; discussion 18-9. PMID: 7693417.
      Citations: 8     Fields:    Translation:Humans
    421. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Fraschini G, Buzdar AU, Frye D, Gibbs HR, Hortobagyi GN. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr. 1993; (15):161-9. PMID: 7912522.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    422. Theriault RL, Stallings CB, Buzdar AU. Pregnancy and breast cancer: clinical and legal issues. Am J Clin Oncol. 1992 Dec; 15(6):535-9. PMID: 1333169.
      Citations: 1     Fields:    Translation:Humans
    423. Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. Ann Intern Med. 1992 Nov 01; 117(9):771-7. PMID: 1416579.
      Citations: 12     Fields:    Translation:Humans
    424. Voravud N, el-Naggar AK, Balch CM, Theriault RL. Metastatic lobular breast carcinoma simulating primary colon cancer. Am J Clin Oncol. 1992 Aug; 15(4):365-9. PMID: 1514536.
      Citations: 5     Fields:    Translation:Humans
    425. Vassilopoulou-Sellin R, Cangir A, Samaan NA. Acanthosis nigricans and severe insulin resistance in an adolescent girl with thyroid cancer: clinical response to antineoplastic therapy. Am J Clin Oncol. 1992 Jun; 15(3):273-6. PMID: 1590285.
      Citations:    Fields:    Translation:Humans
    426. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol. 1992 Jun; 10(6):1014-24. PMID: 1588366.
      Citations: 73     Fields:    Translation:Humans
    427. Jaiyesimi IA, Buzdar AU. Adjuvant chemotherapy in high-risk breast cancer patients with ten or more positive lymph nodes. Am J Clin Oncol. 1992 Apr; 15(2):180-3. PMID: 1313203.
      Citations:    Fields:    Translation:Humans
    428. Buzdar AU, Kau SW, Hortobagyi GN, Ames FC, Holmes FA, Fraschini G, Hug V, Theriault RL, McNeese MD, Singletary SE. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 1992 Jan 15; 69(2):448-52. PMID: 1728373.
      Citations: 11     Fields:    Translation:Humans
    429. Walters RS, Frye D, Buzdar AU, Holmes FA, Hortobagyi GN. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer. 1992 Jan 15; 69(2):476-81. PMID: 1728377.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    430. Simmons JR, Buzdar AU, Ota DM, Marts K, Hortobagyi GN. Complications associated with indwelling catheters. Med Pediatr Oncol. 1992; 20(1):22-5. PMID: 1727207.
      Citations: 1     Fields:    Translation:Humans
    431. Macheledt JE, Buzdar AU, Hortobagyi GN, Frye DK, Gutterman JU, Holmes FA. Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1991 Aug; 18(3):165-70. PMID: 1756259.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    432. Lamki LM, Buzdar AU, Singletary SE, Rosenblum MG, Bhadkamkar V, Esparza L, Podoloff DA, Zukiwski A, Hortobagyi GN, Murray JL. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. J Nucl Med. 1991 Jul; 32(7):1326-32. PMID: 2066785.
      Citations: 10     Fields:    Translation:Humans
    433. Ziegler LD, Buzdar AU. Recent advances in the treatment of breast cancer. Am J Med Sci. 1991 May; 301(5):337-52. PMID: 2021157.
      Citations:    Fields:    Translation:Humans
    434. Ziegler LD, Buzdar AU. Current status of adjuvant therapy of early breast cancer. Am J Clin Oncol. 1991 Apr; 14(2):101-10. PMID: 2028918.
      Citations: 2     Fields:    Translation:Humans
    435. Wallerstein R, Spitzer G, Dunphy F, Huan S, Hortobagyi G, Yau J, Buzdar A, Holmes F, Theriault R, Ewer M, et al. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol. 1990 Nov; 8(11):1782-8. PMID: 2121909.
      Citations: 5     Fields:    Translation:Humans
    436. Buzdar AU, Hortobagyi GN. Sixteen-week, dose-intense chemotherapy in adjuvant treatment of breast cancer. J Natl Cancer Inst. 1990 Jul 18; 82(14):1220-1. PMID: 2362293.
      Citations:    Fields:    Translation:Humans
    437. Holmes FA, Fritsche HA, Loewy JW, Geitner AM, Sutton RC, Buzdar AU, Hortobagyi GN. Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay. J Clin Oncol. 1990 Jun; 8(6):1025-35. PMID: 2189952.
      Citations: 5     Fields:    Translation:Humans
    438. Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer. 1990 Feb 15; 65(4):847-50. PMID: 2297653.
      Citations: 16     Fields:    Translation:Humans
    439. Buzdar AU, McNeese MD, Hortobagyi GN, Smith TL, Kau S, Fraschini G, Hug V, Ellerbroek N, Holmes FA, Ames F, et al. Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer? Cancer. 1990 Feb 01; 65(3):394-9. PMID: 2297630.
      Citations: 8     Fields:    Translation:Humans
    440. Hortobagyi GN, Theriault RL, Frye D, Walters RS, Fraschini G, Tashima CK, Ro JS, Salewski E, Buzdar AU. Pirarubicin in combination chemotherapy for metastatic breast cancer. Am J Clin Oncol. 1990; 13 Suppl 1:S54-6. PMID: 2291460.
      Citations: 2     Fields:    Translation:Humans
    441. Buzdar AU. Current status of endocrine treatment of carcinoma of the breast. Semin Surg Oncol. 1990; 6(2):77-82. PMID: 2180045.
      Citations:    Fields:    Translation:Humans
    442. Buzdar AU, Hortobagyi GN, Esparza LT, Holmes FA, Ro JS, Fraschini G, Lichtiger B. Elliptinium acetate in metastatic breast cancer--a phase II study. Oncology. 1990; 47(2):101-4. PMID: 2314820.
      Citations: 3     Fields:    Translation:Humans
    443. Theriault RL, Buzdar AU. Acute superior vena caval thrombosis after central venous catheter removal: successful treatment with thrombolytic therapy. Med Pediatr Oncol. 1990; 18(1):77-80. PMID: 2152960.
      Citations: 2     Fields:    Translation:Humans
    444. Hortobagyi GN, Dunphy F, Buzdar AU, Spitzer G. Dose intensity studies in breast cancer--autologous bone marrow transplantation. Prog Clin Biol Res. 1990; 354B:195-209. PMID: 2236166.
      Citations:    Fields:    Translation:Humans
    445. Koh EH, Buzdar AU, Ames FC, Singletary SE, McNeese MD, Frye D, Holmes FA, Fraschini G, Hug V, Theriault RL, et al. Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience. Cancer Chemother Pharmacol. 1990; 27(2):94-100. PMID: 2249339.
      Citations: 5     Fields:    Translation:Humans
    446. Vanek N, Hortobagyi GN, Buzdar AU. Radiotherapy enhances the toxicity of aminoglutethimide. Med Pediatr Oncol. 1990; 18(2):162-4. PMID: 2154663.
      Citations:    Fields:    Translation:Humans
    447. Patel HZ, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer. 1989 Oct 15; 64(8):1583-5. PMID: 2676137.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    448. Thoms WW, McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989 Oct; 17(4):739-45. PMID: 2487034.
      Citations: 7     Fields:    Translation:Humans
    449. Hortobagyi GN, Hug V, Buzdar AU, Kau SW, Holmes FA, Fritsche HA. Sequential cyclic combined hormonal therapy for metastatic breast cancer. Cancer. 1989 Sep 01; 64(5):1002-6. PMID: 2527085.
      Citations: 1     Fields:    Translation:Humans
    450. Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol. 1989 Apr; 12(2):123-8. PMID: 2705401.
      Citations: 7     Fields:    Translation:Humans
    451. Chu PS, Buzdar AU, Hortobagyi GN. Trilostane with hydrocortisone in treatment of metastatic breast cancer. Breast Cancer Res Treat. 1989 Mar; 13(2):117-21. PMID: 2659103.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    452. McCready DR, Hortobagyi GN, Kau SW, Smith TL, Buzdar AU, Balch CM. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg. 1989 Jan; 124(1):21-5. PMID: 2910244.
      Citations: 27     Fields:    Translation:Humans
    453. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988 12 29; 319(26):1681-92. PMID: 3205265.
      Citations: 125     Fields:    Translation:Humans
    454. Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988 Dec 15; 62(12):2507-16. PMID: 3056604.
      Citations: 71     Fields:    Translation:Humans
    455. Buzdar AU, Hortobagyi GN, Smith TL, Kau S, Marcus C, Holmes FA, Hug V, Fraschini G, Ames FC, Martin RG. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer. 1988 Nov 15; 62(10):2098-104. PMID: 3179922.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    456. Hortobagyi GN, Buzdar AU. Management of locally advanced breast cancer. Am J Clin Oncol. 1988 Oct; 11(5):597-601. PMID: 2845771.
      Citations: 3     Fields:    Translation:Humans
    457. Skinner WL, Buzdar AU, Libshitz HI. Massive osteolysis of the right clavicle developing after radiation therapy. JAMA. 1988 Jul 15; 260(3):375-6. PMID: 3379746.
      Citations:    Fields:    Translation:HumansPHPublic Health
    458. Buzdar AU. Chemotherapeutic approaches to advanced breast cancer. Semin Oncol. 1988 Jun; 15(3 Suppl 4):65-70. PMID: 3293220.
      Citations: 1     Fields:    Translation:Humans
    459. Berté E, Buzdar AU, Smith TL, Hortobagyi GN. Bilateral primary breast cancer in patients treated with adjuvant therapy. Am J Clin Oncol. 1988 Apr; 11(2):114-8. PMID: 3128945.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    460. Fraschini G, Charnsangavej C, Carrasco CH, Buzdar AU, Jabboury KW, Hortobagyi GN. Percutaneous hepatic arterial infusion of cisplatin-vinblastine for refractory breast carcinoma metastatic to the liver. Am J Clin Oncol. 1988 Feb; 11(1):34-8. PMID: 3277374.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    461. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology. 1988; 45(5):344-5. PMID: 3412740.
      Citations: 29     Fields:    Translation:Humans
    462. Hortobagyi GN, Buzdar AU, Frye D, Hug V, Fraschini G, Ames FC, Montague E, Gutterman JU, Martin RG. Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial. Cancer. 1987 Dec 01; 60(11):2596-604. PMID: 3315173.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    463. Hortobagyi GN, Frye D, Holmes FA, Hug V, Fraschini G, Buzdar AU. Phase II study of iproplatin in metastatic breast carcinoma. Cancer Treat Rep. 1987 Dec; 71(12):1193-6. PMID: 3690529.
      Citations: 1     Fields:    Translation:Humans
    464. Fraschini G, Yap HY, Mann G, Buzdar AU, Blumenschein GR, Hortobagyi GN. Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer. Cancer. 1987 Oct 15; 60(8):1724-8. PMID: 3652000.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    465. Moon TE, Jones SE, Bonadonna G, Valagussa P, Powles T, Buzdar A, Montague E. Development and use of a natural history data base of breast cancer studies. Am J Clin Oncol. 1987 Oct; 10(5):396-403. PMID: 3310604.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    466. Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin S, Buzdar A, Montague E, Powles T. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol. 1987 Oct; 10(5):387-95. PMID: 3310603.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    467. Ro J, Buzdar AU, Esparza L, Hortobagyi GN. Phase II study of peplomycin in advanced breast carcinoma. Cancer Treat Rep. 1987 Jul-Aug; 71(7-8):777-8. PMID: 2440571.
      Citations:    Fields:    Translation:Humans
    468. Holmes FA, Yap HY, Esparza L, Buzdar AU, Blumenschein GR, Hug V, Hortobagyi GN. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. Cancer. 1987 Jun 15; 59(12):1992-9. PMID: 3567861.
      Citations: 3     Fields:    Translation:HumansCells
    469. Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol. 1987 May; 5(5):773-82. PMID: 3106583.
      Citations: 32     Fields:    Translation:Humans
    470. Ventura GJ, Buzdar AU, Kau S, Lichtiger B, Hortobagyi GN. Clinical trial of plasma perfusion over immobilized staphylococcal protein A in metastatic breast cancer. Cancer Treat Rep. 1987 Apr; 71(4):411-3. PMID: 3548958.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    471. Hortobagyi GN, Buzdar AU, Bodey GP, Kau S, Rodriguez V, Legha SS, Yap HY, Blumenschein GR. High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol. 1987 Feb; 5(2):178-84. PMID: 3543241.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    472. Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer. 1986 Dec 15; 58(12):2589-93. PMID: 3779609.
      Citations: 25     Fields:    Translation:Humans
    473. Larroquette CA, Hortobagyi GN, Buzdar AU, Holmes FA. Subclinical hepatic toxicity during combination chemotherapy for breast cancer. JAMA. 1986 Dec 05; 256(21):2988-90. PMID: 3773217.
      Citations: 5     Fields:    Translation:Humans
    474. Kramer A, Buzdar AU. Inflammatory breast carcinoma. Am J Clin Oncol. 1986 Dec; 9(6):541-3. PMID: 3024479.
      Citations:    Fields:    Translation:Humans
    475. Hortobagyi GN, Buzdar AU. Progress in inflammatory breast cancer: cause for cautious optimism. J Clin Oncol. 1986 Dec; 4(12):1727-9. PMID: 3783199.
      Citations: 1     Fields:    Translation:Humans
    476. Polyzos A, Buzdar AU. Complete remission with combination chemotherapy in metastatic breast carcinoma. Am J Clin Oncol. 1986 Aug; 9(4):361-3. PMID: 3751975.
      Citations:    Fields:    Translation:Humans
    477. Buzdar AU, Hortobagyi GN. Adjuvant chemotherapy for breast cancer. JAMA. 1986 May 02; 255(17):2296. PMID: 3959318.
      Citations:    Fields:    Translation:Humans
    478. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986 May; 46(5):2578-81. PMID: 3697997.
      Citations: 64     Fields:    Translation:Humans
    479. Casimir MT, Buzdar AU, Blumenschein GR, Hortobagyi GN, Bodey GP. Phase II study of AMSA and doxorubicin to treat metastatic breast cancer. Oncology. 1986; 43(4):205-7. PMID: 3755230.
      Citations:    Fields:    Translation:Humans
    480. Holmes FA, Esparza L, Yap HY, Buzdar AU, Blumenschein GR, Hortobagyi GN. A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1986; 18(2):157-61. PMID: 3791560.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    481. Buzdar AU, Hortobagyi GN, Marcus CE, Smith TL, Martin R, Gehan EA. Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986; (1):81-5. PMID: 3534594.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    482. Lee RW, Buzdar AU, Blumenschein GR, Hortobagyi GN. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer. 1986 Jan 01; 57(1):40-3. PMID: 3940620.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    483. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986; (1):105-9. PMID: 3534581.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    484. Hortobagyi GN, Buzdar AU, Blumenschein GR, Yap HY, Hersh EM. Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. Dev Biol Stand. 1986; 58 ( Pt A):357-63. PMID: 3596041.
      Citations:    Fields:    Translation:Humans
    485. Pasterz RB, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. Cancer. 1985 Nov 15; 56(10):2381-4. PMID: 4042070.
      Citations: 3     Fields:    Translation:Humans
    486. Mann GB, Hortobagyi GN, Buzdar AU, Yap HY, Valdivieso M. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer. Cancer. 1985 Sep 15; 56(6):1320-4. PMID: 4027872.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    487. Messeih AA, Lipton A, Santen RJ, Harvey HA, Boucher AE, Murray R, Ragaz J, Buzdar AU, Nagel GA, Henderson IC. Aminoglutethimide-induced hematologic toxicity: worldwide experience. Cancer Treat Rep. 1985 Sep; 69(9):1003-4. PMID: 4028032.
      Citations: 3     Fields:    Translation:Humans
    488. Fraschini G, Yap HY, Hortobagyi GN, Buzdar A, Blumenschein G. Five-day continuous-infusion vinblastine in the treatment of breast cancer. Cancer. 1985 Jul 15; 56(2):225-9. PMID: 4005794.
      Citations: 6     Fields:    Translation:Humans
    489. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 1985 Jun 15; 55(12):2761-5. PMID: 3922612.
      Citations: 63     Fields:    Translation:Humans
    490. Fastenberg NA, Martin RG, Buzdar AU, Hortobagyi GN, Montague ED, Blumenschein GR, Jessup JM. Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol. 1985 Apr; 8(2):134-41. PMID: 3841746.
      Citations: 3     Fields:    Translation:Humans
    491. Ross MB, Buzdar AU, Smith TL, Eckles N, Hortobagyi GN, Blumenschein GR, Freireich EJ, Gehan EA. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer. 1985 Jan 15; 55(2):341-6. PMID: 3965092.
      Citations: 17     Fields:    Translation:Humans
    492. Feldman LD, Buzdar AU, Blumenschein GR. High-dose 1-beta-D-arabinofuranosylcytosine in advanced breast cancer. Oncology. 1985; 42(5):273-4. PMID: 4034143.
      Citations:    Fields:    Translation:Humans
    493. Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR, Montague ED. Induction chemotherapy of breast cancer. Prog Clin Biol Res. 1985; 201:105-16. PMID: 4095105.
      Citations:    Fields:    Translation:Humans
    494. Hortobagyi GN, Buzdar AU, Frye D, Yap HY, Hug V, Pinnamaneni K, Fraschini G, Halvorson HC, Blumenschein GR. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1985; 5(3):321-6. PMID: 3161565.
      Citations: 11     Fields:    Translation:Humans
    495. Buzdar AU, Hortobagyi GN. Comment on 'Long-term tamoxifen adjuvant therapy in node positive breast cancer'. Breast Cancer Res Treat. 1985; 6(2):149-50. PMID: 4052642.
      Citations:    Fields:    Translation:Humans
    496. Buzdar AU, Blumenschein GR. Breast cancer. Cancer Treat Rev. 1984 Dec; 11(4):315-9. PMID: 6534512.
      Citations:    Fields:    Translation:Humans
    497. Kantarjian HM, Hortobagyi GN, Smith TL, Blumenschein GR, Montague E, Buzdar AU, Martin RG. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol. 1984 Nov; 20(11):1353-61. PMID: 6548710.
      Citations: 2     Fields:    Translation:Humans
    498. Moon TE, Jones SE, Bonadonna G, Powles TJ, Rivkin S, Buzdar A, Montague E. Using a database of protocol studies to evaluate therapy: a breast cancer example. Stat Med. 1984 Oct-Dec; 3(4):333-9. PMID: 6528133.
      Citations:    Fields:    Translation:Humans
    499. Holmes FA, Yap HY, Esparza L, Buzdar AU, Hortobagyi GN, Blumenschein GR. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. Semin Oncol. 1984 Sep; 11(3 Suppl 1):28-31. PMID: 6385262.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    500. Buzdar AU. Adjuvant therapy of breast cancer. Tex Med. 1984 Sep; 80(9):37-8. PMID: 6484865.
      Citations:    Fields:    Translation:Humans
    501. Aboud A, Buzdar AU, Yap HY, Hortobagyi GN, Blumenschein GR. Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. J Surg Oncol. 1984 Jul; 26(3):205-7. PMID: 6610802.
      Citations:    Fields:    Translation:Humans
    502. Smith L, Buzdar AU, Rusch V, Blocker SH, McKenna RJ. Post-mastectomy angiosarcoma: case report and review of the literature. Tex Med. 1984 Jul; 80(7):43-4. PMID: 6379971.
      Citations:    Fields:    Translation:Humans
    503. Finnerty NA, Buzdar AU, Blumenschein GR. Radiation-induced breast cancer. Arch Intern Med. 1984 Jun; 144(6):1217-9. PMID: 6732380.
      Citations: 1     Fields:    Translation:Humans
    504. Pinnamaneni K, Yap HY, Buzdar AU, Distefano A, Blumenschein GR. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone. Cancer. 1984 May 01; 53(9):1841-4. PMID: 6546706.
      Citations: 1     Fields:    Translation:Humans
    505. Legha SS, Ajani JA, Blumenschein GR, Hortobagyi GN, Buzdar AU. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer. 1984 May 01; 53(9):1836-40. PMID: 6231092.
      Citations: 1     Fields:    Translation:Humans